Best in Biotech 19 Aug 2022 Five emerging biotech hubs in the Asia-Pacific region The Asia-Pacific (APAC) region is the third largest pharmaceutical market in the world, and has seen a shift from predominantly producing generics to developing innovative technologies. Here are five emerging biotech hubs in the region to keep an eye on. The life sciences industry is seeing rapid growth in the APAC region – home to […] August 19, 2022 - 7 minutesmins - By Omnia Ibrahim Share WhatsApp Twitter Linkedin Email
News and Trends 18 Aug 2022 First patient on Innovative Cellular Therapeutics’ study looking at treating colorectal cancer The first patient has been enrolled on a study to trial a treatment for relapsed or refractory metastatic colorectal cancer (R/R mCRC) in the U.S. Innovative Cellular Therapeutics (ICT), Inc. a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen receptor (CAR) T cell therapies made the announcement today (August 18). Tolerability The study […] August 18, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Aug 2022 Lung cancer trial patients responding well to combination treatment offered by HUTCHMED and AstraZeneca A medication used to treat non-small cell lung carcinomas (NSCLC) with specific mutations has demonstrated a 49% objective response rate (ORR) in patients. AstraZeneca and HUTCHMED announced that TAGRISSO Plus Savolitinib – a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor – was helping patients with high levels of mesenchymal epithelial transition (MET). […] August 8, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Aug 2022 HUTCHMED drug in colorectal cancer trial meets primary endpoint A trial to look at the use of a drug targeting refractory metastatic colorectal cancer (CRC) has met its primary endpoint of overall survival (OS) in patients with the disease. China’s HUTCHMED Limited announced today (August 8) that the phase 3 FRESCO-2 trial investigating the use of fruquintinib had met all secondary endpoints too. The […] August 8, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Aug 2022 Epigenic Therapeutics raises $20M for gene editing technology Epigenic Therapeutics Co., Ltd., a Chinese biotech gene editing company, has secured $20 million in Series Angel and Pre-A funding. The Series Pre-A funding came from investments by Morningside Venture Capital, Kingray Capital, Trinity Innovation Fund and TigerYeah Capital. Angel investor FountainBridge Capital is also participating. The proceeds will be used to advance the company’s […] August 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Aug 2022 Sanofi and Innovent Biologics to collaborate on oncology medicines and boost China presence Sanofi and Innovent Biologics are to collaborate on providing medicines to patients in China with difficult-to-treat cancers. Innovent is a biopharmaceutical company with clinical development capabilities and a broad commercial footprint in China. Both companies said they are committed to accelerating the development and commercialization of two Sanofi key clinical stage oncology assets: Phase III […] August 4, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 4 Aug 2022 The biggest Asia-Pacific biotech investments in July 2022 China’s vaccine developer MaxHealth Biotechnology raised the biggest private biotech investment in the Asia-Pacific region in July 2022, followed by China Immunotech and Ruibo Bio. MaxHealth Biotechnology reigned supreme in the Asia-Pacific region’s private biotech investment sphere in July 2022, with a $74 million Series B round. The company will use the money to fuel […] August 4, 2022 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 3 Aug 2022 Patients with advanced cancer set to benefit from ProfoundBio’s new drug Patients with ovarian, endometrial, breast, non-small cell lung cancers and mesothelioma could benefit from an antibody drug conjugate (ADC) after clearance of an investigational new drug (IND) was approved by the US Food and Drug Administration (FDA). ProfoundBio received the FDA’s ‘study may proceed’ letter today (August 3) to evaluate PRO1184, a folate receptor […] August 3, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 3 Aug 2022 Ascletis announces FDA clearance of oral drug to conduct study in mild to moderate COVID-19 patients A randomized, placebo-controlled study in mild to moderate COVID-19 patients has been approved by the US Food and Drug Administration (FDA). The Investigational New Drug (IND) application for ASC10, an oral drug candidate targeting RNA-dependent RNA polymerase (RdRp) for COVID-19 was granted to China-based Ascletis Pharma Inc today (August 3), to conduct a Phase 1b […] August 3, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Aug 2022 Zenas BioPharma gets Chinese approval for thyroid eye disease treatment study Zenas BioPharma has received approval of its Investigational New Drug (IND) application from the National Medical Products Administration (NMPA) of China to start a phase 1/2 clinical study of ZB001 to treat thyroid eye disease (TED). The main objective of the study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ZB001. About […] August 1, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2022 Macao university research finds mRNA vaccine booster offers more protection against Omicron variants A study in Macao has found people taking the BioNTech mRNA vaccine as the third booster dose produce more neutralizing antibodies against Omicron variants. The study, led by Daniel Baptista-Hon, assistant professor at the Faculty of Medicine at the Macau University of Science and Technology (M.U.S.T.), and Ligong Lu, director of Zhuhai People’s Hospital, was […] July 25, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2022 Business looks to grow life sciences sector in China A Shanghai business says its top priority is to carry on contributing to the rapid growth of the life sciences sector in China. The ATLATL Center for Innovation & Research is a biopharma research-based open platform that builds laboratories and office spaces equipped with professional research and development (R&D) services, lab facilities and operations management. […] July 20, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email